{"entity":{"id":"trop2","kind":"target","name":"TROP2","aka":[],"tldr":"TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients.","summary":"Trophoblast cell-surface antigen 2 is a transmembrane glycoprotein overexpressed in most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) with low normal-tissue expression. It is not an oncogenic driver; it is a delivery address. Three TROP2 ADCs are approved or in registration (sacituzumab govitecan, datopotamab deruxtecan, sacituzumab tirumotecan) and a TROP2 PET tracer is in development to select patients.","asOf":"2026-10-06","links":[{"label":"UniProt P09758: TACSTD2 (TROP2)","url":"https://www.uniprot.org/uniprotkb/P09758/entry"},{"label":"Bardia et al., ASCENT biomarker analysis (Ann Oncol 2021)","url":"https://doi.org/10.1016/j.annonc.2021.06.002"},{"label":"TRODELVY prescribing information (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d"},{"label":"DATROWAY prescribing information (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0"}],"tags":["adc-target","pet-target"],"related":["trop2-expression"],"cancers":["tnbc","breast-hr-positive","nsclc","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["ak146d1","bio-106","datopotamab-deruxtecan","eb-nk-301","lcb84","sacituzumab-govitecan","sacituzumab-tirumotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04617522","nct05922930","nct06311214","nct06454890","nct06902389","nct06929663","nct07067567","nct07101432","nct07299747","nct07377526","nct07509008","nct07553390","nct07631013"],"people":[],"bottlenecks":[],"keyPapers":["paper-bardia-ascent-trop2-biomarker-ann-oncol-2021"],"journals":[],"dependsOn":[],"notes":["Triple-negative breast cancer: sacituzumab govitecan benefit was seen at high and medium Trop-2 H-score in ASCENT with a low group too small to judge (Bardia 2021); no label requires the test. TACSTD2 amplification is rare, 2.5 to 4.4% (cBioPortal)."],"symbol":"TACSTD2","role":[],"sources":[],"specificity":"tumour-associated","distribution":"few-types","specificityNote":"Tumour-associated overexpression: 6 cell-killing or cell-finding medicines (AK146D1, BIO-106, Datopotamab deruxtecan and more) aim at the antigen, which HPA finds stained high in 1 normal tissue; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA TACSTD2: RNA tissue enhanced (esophagus 1,245 nTPM, salivary gland 585 nTPM, skin 1 555 nTPM); blood lineage group enriched (dendritic cells 4 nTPM, granulocytes 15 nTPM, monocytes 4 nTPM); high antibody staining in 1 normal tissue; highest cancer staining urothelial cancer (1 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Lung cancer (all types), Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma); approvals of single-target medicines aimed at it also list Endometrial cancer, Cervical cancer, not counted; Open Targets associates it with 3 specific cancer types at or above 0.5 (breast cancer, non-small cell lung carcinoma, triple-negative breast carcinoma). (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas TACSTD2 tissue","url":"https://www.proteinatlas.org/ENSG00000184292-TACSTD2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas TACSTD2 pathology","url":"https://www.proteinatlas.org/ENSG00000184292-TACSTD2/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000184292 associations","url":"https://platform.opentargets.org/target/ENSG00000184292/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:11530","ensembl":"ENSG00000184292","uniprot":"P09758","entrez":"4070","firstDescribed":1989,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Linnenbach A.J. et al, Proc. Natl. Acad. Sci. U.S.A, 1989, \"Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2911574/","biology":"Regulates calcium signalling and cell adhesion; overexpression correlates with shorter survival. Expression is heterogeneous within tumours, which limits the value of IHC selection. Internalises on antibody binding and traffics to lysosomes, which is what makes it a good ADC target.","whereFound":["Triple-negative breast cancer (~80-90% express)","HR+ breast cancer","NSCLC","Urothelial carcinoma","Gastric, pancreatic, endometrial cancers","Triple-negative breast cancer: gene amplification (copy number) 2.5-4.4%"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"tnbc","pct":"80-90","measure":"IHC, any/moderate-high expression","source":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13059868/","note":"ASCENT's exploratory biomarker analysis supported benefit in the high/medium H-score groups; the low-expression group was too small for definitive conclusions (290 of 468 assessable patients had TROP2 data). No TROP2 companion test is required for the breast-cancer indications."},{"cancerId":"breast-hr-positive","pct":"75-90","measure":"IHC, any expression","source":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13059868/"},{"cancerId":"nsclc","pct":"60-70","measure":"IHC, moderate-high","source":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13059868/","note":"Adenocarcinoma and squamous"},{"cancerId":"urothelial","pct":"80-90","measure":"IHC, any expression","source":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13059868/"},{"cancerId":"pancreatic","pct":50,"measure":"IHC, any expression","source":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13059868/","note":"Approximate; heterogeneous"},{"cancerId":"tnbc","pct":"2.5-4.4","measure":"Gene amplification (copy number)","source":"https://www.cbioportal.org/study/summary?id=brca_tcga_pan_can_atlas_2018","note":"Trop-2 expression was assessable in 290 of 468 ASCENT patients and sacituzumab govitecan benefit was seen at high and medium expression (progression-free survival 6.9 and 5.6 versus 2.5 and 2.2 months), with the low group too small to judge (Bardia 2021); cBioPortal: TACSTD2 amplification in the TNBC-filtered copy-number cohorts, 3 of 119, 2.5%, in brca_tcga_pan_can_atlas_2018 and 14 of 320, 4.4%, in brca_metabric; no TACSTD2 mutation in either."}]},"route":"/targets/trop2/","neighbours":{"biomarker":[{"id":"trop2-expression","kind":"biomarker","name":"TROP2 expression","route":"/biomarkers/trop2-expression/"}],"cancer":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"9mw2921","kind":"drug","name":"9MW2921","route":"/drugs/9mw2921/"},{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/"},{"id":"asp2998","kind":"drug","name":"ASP2998","route":"/drugs/asp2998/"},{"id":"avzo-103","kind":"drug","name":"AVZO-103","route":"/drugs/avzo-103/"},{"id":"bat8008","kind":"drug","name":"BAT8008","route":"/drugs/bat8008/"},{"id":"bcg033","kind":"drug","name":"BCG033","route":"/drugs/bcg033/"},{"id":"bhv-1510","kind":"drug","name":"BHV-1510","route":"/drugs/bhv-1510/"},{"id":"bio-106","kind":"drug","name":"BIO-106","route":"/drugs/bio-106/"},{"id":"can020","kind":"drug","name":"CAN020","route":"/drugs/can020/"},{"id":"catb-101","kind":"drug","name":"CATB-101","route":"/drugs/catb-101/"},{"id":"cbb-120","kind":"drug","name":"CBB-120","route":"/drugs/cbb-120/"},{"id":"ctph-03","kind":"drug","name":"CTPH-03","route":"/drugs/ctph-03/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"db-1305","kind":"drug","name":"DB-1305 / BNT325","route":"/drugs/db-1305/"},{"id":"eb-nk-301","kind":"drug","name":"EB-NK-301","route":"/drugs/eb-nk-301/"},{"id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/"},{"id":"fda018-adc","kind":"drug","name":"FDA018-ADC","route":"/drugs/fda018-adc/"},{"id":"ibi130","kind":"drug","name":"IBI130","route":"/drugs/ibi130/"},{"id":"ibi3014","kind":"drug","name":"IBI3014","route":"/drugs/ibi3014/"},{"id":"js108","kind":"drug","name":"JS108","route":"/drugs/js108/"},{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/"},{"id":"kh815","kind":"drug","name":"KH815","route":"/drugs/kh815/"},{"id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/"},{"id":"mt-302","kind":"drug","name":"MT-302","route":"/drugs/mt-302/"},{"id":"pf-06664178","kind":"drug","name":"PF-06664178","route":"/drugs/pf-06664178/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"},{"id":"shr-a1921","kind":"drug","name":"SHR-A1921","route":"/drugs/shr-a1921/"},{"id":"sti-3258","kind":"drug","name":"STI-3258","route":"/drugs/sti-3258/"},{"id":"trop2-car-il15-cord-blood-nk","kind":"drug","name":"TROP2 CAR/IL-15 cord-blood NK cells","route":"/drugs/trop2-car-il15-cord-blood-nk/"},{"id":"vbc103","kind":"drug","name":"VBC103","route":"/drugs/vbc103/"}],"trial":[{"id":"nct05923008","kind":"trial","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05923008/"},{"id":"nct06902389","kind":"trial","name":"A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma","route":"/trials/nct06902389/"},{"id":"nct06966700","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","route":"/trials/nct06966700/"},{"id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","route":"/trials/nct06384807/"},{"id":"nct04601285","kind":"trial","name":"A Phase I Study of JS108 in Patients With Advanced Solid Tumors","route":"/trials/nct04601285/"},{"id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/"},{"id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","route":"/trials/nct07533123/"},{"id":"nct06564844","kind":"trial","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","route":"/trials/nct06564844/"},{"id":"nct07067567","kind":"trial","name":"A Study of AK146D1 for Injection in Advanced Solid Tumors","route":"/trials/nct07067567/"},{"id":"nct06929663","kind":"trial","name":"A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors","route":"/trials/nct06929663/"},{"id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","route":"/trials/nct07287995/"},{"id":"nct06130553","kind":"trial","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","route":"/trials/nct06130553/"},{"id":"nct05174637","kind":"trial","name":"A Study of FDA018-ADC in Patients With Advanced Solid Tumors","route":"/trials/nct05174637/"},{"id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","route":"/trials/nct06464055/"},{"id":"nct02122146","kind":"trial","name":"A Study Of PF-06664178 In Patients With Advanced Solid Tumors","route":"/trials/nct02122146/"},{"id":"nct06312176","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","route":"/trials/nct06312176/"},{"id":"nct06841354","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","route":"/trials/nct06841354/"},{"id":"nct06312137","kind":"trial","name":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm","route":"/trials/nct06312137/"},{"id":"nct05941507","kind":"trial","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","route":"/trials/nct05941507/"},{"id":"nct06417814","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan","route":"/trials/nct06417814/"},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/"},{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/"},{"id":"nct04639986","kind":"trial","name":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","route":"/trials/nct04639986/"},{"id":"nct04434040","kind":"trial","name":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","route":"/trials/nct04434040/"},{"id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","route":"/trials/nct07193511/"},{"id":"nct06454890","kind":"trial","name":"Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06454890/"},{"id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07299747/"},{"id":"nct05555732","kind":"trial","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","route":"/trials/nct05555732/"},{"id":"nct06953089","kind":"trial","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06953089/"},{"id":"diamond","kind":"trial","name":"DIAMOND","route":"/trials/diamond/"},{"id":"nct06358430","kind":"trial","name":"Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)","route":"/trials/nct06358430/"},{"id":"nct05620017","kind":"trial","name":"Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection","route":"/trials/nct05620017/"},{"id":"nct05438329","kind":"trial","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","route":"/trials/nct05438329/"},{"id":"nct06974812","kind":"trial","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06974812/"},{"id":"nct06885645","kind":"trial","name":"KH815 first-in-human study","route":"/trials/nct06885645/"},{"id":"nct06081244","kind":"trial","name":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","route":"/trials/nct06081244/"},{"id":"nct07178730","kind":"trial","name":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","route":"/trials/nct07178730/"},{"id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","route":"/trials/nct06422143/"},{"id":"nct06311214","kind":"trial","name":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","route":"/trials/nct06311214/"},{"id":"nct06066424","kind":"trial","name":"Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)","route":"/trials/nct06066424/"},{"id":"nct07631013","kind":"trial","name":"Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions","route":"/trials/nct07631013/"},{"id":"nct07589530","kind":"trial","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","route":"/trials/nct07589530/"},{"id":"nct07509008","kind":"trial","name":"Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum","route":"/trials/nct07509008/"},{"id":"nct07553390","kind":"trial","name":"Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers","route":"/trials/nct07553390/"},{"id":"nct07101432","kind":"trial","name":"Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)","route":"/trials/nct07101432/"},{"id":"nct05990452","kind":"trial","name":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors","route":"/trials/nct05990452/"},{"id":"nct06350097","kind":"trial","name":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L","route":"/trials/nct06350097/"},{"id":"nct05687266","kind":"trial","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","route":"/trials/nct05687266/"},{"id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","route":"/trials/nct06357533/"},{"id":"nct07069595","kind":"trial","name":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","route":"/trials/nct07069595/"},{"id":"nct07628504","kind":"trial","name":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","route":"/trials/nct07628504/"},{"id":"nct07788222","kind":"trial","name":"Sacituzumab Govitecan and Q901 in Advanced TNBC","route":"/trials/nct07788222/"},{"id":"nct06238921","kind":"trial","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","route":"/trials/nct06238921/"},{"id":"nct04595565","kind":"trial","name":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","route":"/trials/nct04595565/"},{"id":"nct04230109","kind":"trial","name":"Sacituzumab Govitecan In TNBC","route":"/trials/nct04230109/"},{"id":"nct06170788","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P","route":"/trials/nct06170788/"},{"id":"nct06393374","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","route":"/trials/nct06393374/"},{"id":"nct06074588","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With","route":"/trials/nct06074588/"},{"id":"nct06305754","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A","route":"/trials/nct06305754/"},{"id":"nct05347134","kind":"trial","name":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct05347134/"},{"id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/"},{"id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","route":"/trials/nct05489211/"},{"id":"nct05215340","kind":"trial","name":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab","route":"/trials/nct05215340/"},{"id":"nct04892342","kind":"trial","name":"Study of ESG401 in Adults With Solid Tumors","route":"/trials/nct04892342/"},{"id":"nct06167317","kind":"trial","name":"Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors","route":"/trials/nct06167317/"},{"id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","route":"/trials/nct06942234/"},{"id":"nct05969041","kind":"trial","name":"Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","route":"/trials/nct05969041/"},{"id":"nct05609968","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","route":"/trials/nct05609968/"},{"id":"nct04617522","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment","route":"/trials/nct04617522/"},{"id":"nct05922930","kind":"trial","name":"Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer","route":"/trials/nct05922930/"},{"id":"nct05060276","kind":"trial","name":"Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors","route":"/trials/nct05060276/"},{"id":"nct06592417","kind":"trial","name":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors","route":"/trials/nct06592417/"},{"id":"nct07377526","kind":"trial","name":"TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer","route":"/trials/nct07377526/"},{"id":"nct06851663","kind":"trial","name":"Trop2-targeted immunoPET Imaging of Solid Tumors","route":"/trials/nct06851663/"},{"id":"tropics-02","kind":"trial","name":"TROPiCS-02","route":"/trials/tropics-02/"},{"id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/"},{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/"},{"id":"tropion-lung05","kind":"trial","name":"TROPION-Lung05","route":"/trials/tropion-lung05/"},{"id":"nct07291037","kind":"trial","name":"TROPION-Lung17","route":"/trials/nct07291037/"}],"paper":[{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/"},{"id":"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","kind":"paper","name":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","route":"/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/"},{"id":"paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022","kind":"paper","name":"Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/"},{"id":"paper-tropion-breast02-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","route":"/key-papers/paper-tropion-breast02-ann-oncol-2026/"},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/"}],"term":[{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/"},{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/"},{"id":"overexpression","kind":"term","name":"Overexpression","route":"/terms/overexpression/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"},{"id":"trop2-adc-roadmap","kind":"roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/"}],"idea":[{"id":"idea-tnbc-adc-sequencing-trial","kind":"idea","name":"A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer","route":"/ideas/idea-tnbc-adc-sequencing-trial/"},{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/"},{"id":"idea-bio2-myeloid-engager-bispecific","kind":"idea","name":"Bispecific antibodies that engage macrophages instead of T cells","route":"/ideas/idea-bio2-myeloid-engager-bispecific/"},{"id":"idea-dual-payload-first","kind":"idea","name":"Dual-payload ADCs in first line to prevent resistance","route":"/ideas/idea-dual-payload-first/"},{"id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/"},{"id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/"},{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/"},{"id":"idea-bio2-transferrin-shuttle-adc","kind":"idea","name":"Use the brain's own transport door to carry antibody drugs across","route":"/ideas/idea-bio2-transferrin-shuttle-adc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/"},{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/"}],"company":[{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/"},{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/"}],"institution":[{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/"}],"pathway":[{"id":"dna-replication-licensing","kind":"pathway","name":"DNA replication & origin licensing","route":"/pathways/dna-replication-licensing/"},{"id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/"},{"id":"emt","kind":"pathway","name":"Epithelial-mesenchymal transition & drug efflux","route":"/pathways/emt/"}],"pairing":[{"id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","route":"/pairings/trop2-pet-to-adc/"}],"person":[{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/"},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/"},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"}]}}